| abstract |
The present invention relates to the pharmaceutical field and in particular to the treatment of hypopigmentary pathologies and photosensitive dermatosis. More specifically, the invention relates to compounds that are agonists of the MC1R receptor and exhibits reduced toxicity relative to other compounds of the same class. These compounds have the general formula (I) below: in which R 1 represents a cyclopropylmethyl or a 4-hydroxybutyl group; R2 represents a hydrogen atom or a methyl group; and also the salts and enantiomers of the corresponding compounds of the general formula (I). |